Skip to main content
Top
Published in: Abdominal Radiology 8/2020

01-08-2020 | Hepatobiliary

Feasibility of wide detector three-pass arterial phase liver CT in patients with cirrhosis: timing of hyperenhancing lesion peak conspicuity

Authors: Erik V. Soloff, Nitin Desai, Janet M. Busey, Kent M. Koprowicz, William P. Shuman

Published in: Abdominal Radiology | Issue 8/2020

Login to get access

Abstract

Purpose

To evaluate feasibility of a wide detector liver CT protocol with three acquisitions in the hepatic arterial phase.

Methods

Forty-one patients with cirrhosis prospectively underwent a wide detector axial liver CT protocol. Three 16 cm axial liver acquisitions were obtained during a single breath hold at peak aortic enhancement plus 10, 20, and 25 s. Two readers working separately scored overall exam quality, identified hyperenhancing lesions, and subjectively scored and ranked relative lesion conspicuity. Objective lesion enhancement was measured and CNR calculated. Data were analyzed using a generalized linear models and Tukey’s post hoc testing.

Results

Seventy-one hyperenhancing lesions were identified with average size of 1.8 cm (range 0.4–9.6 cm). The two readers separately identified 60 and 54 lesions on the 10 s arterial acquisition, 70 and 67 on the 20 s, and 52 and 51 on the 25 s. The readers determined all exams had diagnostic image quality. Subjective ranking of lesion conspicuity was greatest at 20 s in 62% of lesions but was greatest at 10 or 25 s in 38%. CNR was highest at 20 s in 58% of lesions but was highest at 10 or 25 s in 42%. Overall, there was no significant difference in mean CNR between the three arterial acquisitions.

Conclusion

A wide detector axial liver CT protocol with three acquisitions in the hepatic arterial phase is technologically feasible and results in diagnostic image quality. With this protocol, peak subjective and objective hyperenhancing lesion conspicuity may be earlier or later than 20 s in up to 40% of lesions.
Literature
Metadata
Title
Feasibility of wide detector three-pass arterial phase liver CT in patients with cirrhosis: timing of hyperenhancing lesion peak conspicuity
Authors
Erik V. Soloff
Nitin Desai
Janet M. Busey
Kent M. Koprowicz
William P. Shuman
Publication date
01-08-2020
Publisher
Springer US
Published in
Abdominal Radiology / Issue 8/2020
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-020-02539-x

Other articles of this Issue 8/2020

Abdominal Radiology 8/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine